Sienna biopharmaceuticals, inc. (SNNA)
CashFlow / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-3,970

-8,264

-16,382

-19,335

-16,794

-20,239

-17,103

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-10,107

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

36

37

39

40

39

39

39

40

27

27

26

Amortization of debt discount and issuance costs

201

237

233

-

-

-

-

-

-

-

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

643

86

Stock-based compensation

1,406

871

1,533

1,309

1,495

995

901

1,057

742

180

133

Fair value adjustment of success payment liability

-

-

-

-685

-193

-1,238

-1,166

-2,509

2,459

1,021

1,052

Fair value adjustment of contingent consideration

-33,500

-300

4,600

4,700

-700

800

1,500

-201

1,100

700

1,390

Non-cash interest expense

-158

214

214

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

27

Loss on disposal of property and equipment

-21

-1

-1

-

-

-

-

-

-

-

-

Impairment of operating lease – right-of-use asset

0

0

13

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Prepaid expenses and other current assets

6,961

-92

-383

-1,207

332

384

-506

648

-1,436

1,889

248

Accounts payable and other accrued liabilities

-1,318

-1,305

-3,403

-3,110

133

4,277

868

-631

1,226

638

1,637

Net cash used in operating activities

-17,844

-8,417

-12,769

-15,599

-15,889

-15,750

-14,455

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-6,004

Investment in property and equipment

0

0

4

6

16

13

4

104

96

24

50

Net cash used in investing activities

0

0

-4

-6

-16

-13

-4

-

-

-

-

Financing activities
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-50

Proceeds from issuance of common stock, net of issuance costs, early exercise liability and repurchase of unvested early exercise stock options

0

425

21,442

-57

5,055

407

-18

0

-18

200

6

Debt issuance costs related to long-term debt

-

-

16

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible promissory notes

-

-

-

-

-

-

-

0

0

0

3,906

Net cash provided by financing activities

-20,000

452

21,426

293

4,993

30,692

-18

-

-

-

-

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

3,912

Effect of exchange rate changes on cash

1

3

-10

-137

0

-55

23

51

18

-15

-106

Net decrease in cash, cash equivalents and restricted cash

-37,843

-7,962

8,643

-15,449

-10,912

14,874

-14,454

-14,134

56,882

24,948

-2,248

Supplemental Disclosure of Cash Flow Information:
Right-of-use asset obtained in exchange for lease liability

-669

0

844

-

-

-

-

-

-

-

-

Warrants issued

0

0

1,105

-

-

-

-

-

-

-

-